A Phase 4 interventional study of Metamizole and Placebo in Stroke, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-10.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Stroke by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Stroke · Boehringer Ingelheim.
Among the 23 studies in Stroke by Boehringer Ingelheim, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 1998, is one of 3 in phase 4, and was the 11th registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →None of the 23 studies in Stroke by Boehringer Ingelheim is open now. The open studies under Stroke, anywhere →
Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 48 across 6,037 interventional studies indexed under Stroke.
Median enrollment 686 across the 12 interventional studies, 9,472 across the 11 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Stroke by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clinical efficacy and safety of Metamizole 2 g i.v. versus placebo, as antithermic therapy in the acute phase of ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Metamizole
Drug: Placebo
Assessment of the functional outcome according to the Scandinavian Stroke Scale (SSS)
Time frame: after 30 days
Assessment of functional outcome according to SSS
Time frame: Baseline, after 3 and 7 days
Number of patients with score of SSS < 30 points
Time frame: after 30 days
Clinical impression assessed on the Modified Rankin Scale
Time frame: after 30 days
Effect on the activities of daily living assessed on Barthel Index
Time frame: after 30 days
Number of patients requiring rescue therapy
Time frame: up to 30 days
Duration of hospital stay
Time frame: up to 30 days
Assessment of tympanic temperature
Time frame: up to 3 days after start of treatment
Percentage of mortality
Time frame: after 30 days
Number of patients with adverse events
Time frame: up to 30 days
No study locations are listed for this record.
The record gives a start of Dec 1998 and a primary completion of May 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dipyrone